Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma

被引：0
|
作者：
Rosenberg, J. E.
Weinberg, V. K.
Claros, C.
Ryan, C.
Lin, A. M.
Fong, L.
Brocks, D.
Small, E. J.
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Alberta, Edmonton, AB, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5109
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma
    Harzstark, A. L.
    Rosenberg, J. E.
    Weinberg, V. K.
    Sun, J.
    Ryan, C. J.
    Lin, A. M.
    Fong, L.
    Brocks, D. R.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma
    Kroog, G. S.
    Feldman, D. R.
    Kondagunta, G. V.
    Ginsberg, M. S.
    Fischer, P. M.
    Trinos, M. J.
    Patil, S.
    Ishill, N. M.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
    Jac, J.
    Giessinger, S.
    Khan, M.
    Willis, J.
    Chiang, S.
    Amato, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC).
    Amato, R. J.
    Misellati, A.
    Khan, M.
    Chiang, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 224S - 224S
  • [5] A phase II trial of RAD001 in patients (PTS) with metastatic renal cell carcinoma (MRCC)
    Amato, R.
    Jac, J.
    Giessinger, S.
    Khan, M.
    Willis, J.
    Chiang, S.
    CANCER INVESTIGATION, 2007, 25 : 20 - 21
  • [6] Prediction of response to RAD001 (everolimus) in patients with metastatic renal cell carcinoma
    Seidel, C.
    Fenner, M.
    Merseburger, A.
    Heuser, M.
    Ganser, A.
    Gruenwald, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Prediction of response to RAD001 (Everolimus) in patients with metastatic renal cell carcinoma
    Seidel, C.
    Fenner, M.
    Merseburger, A.
    Heuser, M.
    Ganser, A.
    Gruenwald, V.
    ONKOLOGIE, 2010, 33 : 105 - 105
  • [8] Treatment of refractory metastatic renal cell carcinoma (RCC) with bevacizumab and RAD001
    Hershman, L. C.
    McMillan, A.
    Srinivas, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma
    Oudard, Stephane
    Medioni, Jacques
    Aylllon, Jorge
    Barrascourt, Eduardo
    Elaidi, Reza-Thierry
    Balcaceres, Jose
    Scotte, Florian
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 705 - 717
  • [10] Phase II trial of RAD001 in renal cell carcinoma patients with non-clear cell histology.
    Koh, Youngil
    Kim, Ji Yeon
    Lim, Ho Yeong
    Ahn, Jin-Hee
    Lee, Jae-Lyun
    Rha, Sun Young
    Kim, YuJung
    Kim, Tae Min
    Lee, Se-Hoon
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345